Drift monitoring tracks changes in input data, patient populations, workflow conditions, model output, or user behavior that may affect AI performance. In healthcare, drift can create safety, equity, compliance, or operational risk.
Buyers should ask how drift is detected, who reviews alerts, what thresholds trigger action, and how vendors communicate model or workflow changes.
Application scenario: In workflow review, this term helps teams map a vendor claim to the care setting, data flow, integration point, user handoff, and oversight step where it applies. Procurement impact: Buyers should evaluate evidence, interoperability effort, security and privacy controls, pricing assumptions, support, and compliance responsibilities before shortlisting or contracting for a tool that depends on this capability.
Sources and review notes
These links support definition-level research and do not establish the regulatory status, safety, or suitability of any product.
NIST's AI RMF Playbook recommends monitoring AI functionality and behavior in production, comparing production metrics with predeployment results, and considering data drift, model drift, error propagation, and feedback loops. NIST's 2026 report on deployed-AI monitoring identifies unresolved barriers such as detecting degradation and drift, fragmented logging, scaling human review, and the lack of mature shared methods, so it does not establish a universal metric, cadence, or threshold. FDA's final guidance for predetermined change control plans for AI-enabled device software functions recommends prospectively describing planned modifications, the methods used to develop, validate, and implement them, and their impact. FDA, Health Canada, and MHRA guiding principles also call for scientifically and clinically justified performance methods, before-and-after evidence, transparency, and monitoring, detection, and response to deviations. The FDA materials apply to regulated AI-enabled medical devices and do not determine obligations for every healthcare AI product; a monitoring dashboard or statistical alert alone does not establish clinical degradation or authorize an unreviewed update. Teams must define the intended use, deployment unit, baseline period, reference distribution, outcome and label source, expected seasonality, subgroup and site strata, acceptable range, minimum sample, confidence interval, delay, alert severity, owner, investigation clock, and stop, fallback, rollback, retraining, revalidation, and notification authority before launch. Monitoring should separately cover input schema and missingness, acquisition devices and protocols, patient and language mix, prevalence, label and coding practice, workflow and user behavior, latency and availability, output distribution, calibration, discrimination, false positives and negatives, override and reliance, downstream actions, safety events, equity, vendor model and configuration changes, and feedback loops. Teams should preserve versioned inputs, outputs, context and ground truth; validate alerts with qualified human review; avoid adapting to corrupted labels or post-intervention data without causal analysis; test shadow or staged changes against current and historical cohorts; communicate material limitations; and document why a system remained active, was restricted, or was withdrawn.
